The sight test fee Authors' reply

BMJ 1994; 309 doi: https://doi.org/10.1136/bmj.309.6965.1372 (Published 19 November 1994) Cite this as: BMJ 1994;309:1372

Authors' reply

  1. D A H Laidlaw,
  2. P A Bloom,
  3. V J Marmion,
  4. A O Hughes,
  5. J M Sparrow
  1. Bristol Eye Hospital, Bristol; Department of Epidemiology and Public Health Medicine, University of Bristol; Department of Ophthalmology, University of Bristol

    EDITOR, - Louis Clearkin doubts the value of treatment for glaucoma. In line with most ophthalmologists we favour it: plenty of good quality research has proved that treatment of chronic glaucoma slows or halts its natural progression over many years to blindness.1,2 Clearkin supports his argument with reference to two studies. The first found that only one of 200 patients who underwent surgery for glaucoma became blind before death or during the 20 years of follow up3; we interpret this as successful preservation of vision. The second was a randomised controlled trial comparing medical …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription